Source comparison
Melanotan-2 Safety Studies: Clinical vs Recreational Comparison
University of Arizona trials (1991–1996) 0.025–0.16 mg/kg subcutaneous 8–12 weeks Nausea (56%), flushing (44%), spontaneous erections (70%), BP elevation (40%) Blood pressure only. No ECG or echo None conducted Proof-of-concept only. Insufficient for regulator
This comparison does not assign a generated winner or score.
- University of Arizona trials (1991–1996)
- 0.025–0.16 mg/kg subcutaneous
- 8–12 weeks
- Nausea (56%), flushing (44%), spontaneous erections (70%), BP elevation (40%)
- Blood pressure only. No ECG or echo
- None conducted
- Proof-of-concept only. Insufficient for regulatory approval
- Recreational use patterns (case reports 2005–2026)
- 0.25–1 mg daily (non-weight-adjusted)
- Variable. Weeks to months
- Nausea, hypertension, renal dysfunction, anxiety, libido dysregulation
- Rare. Only when users sought medical care
- No systematic tracking. Melanoma risk unquantified
- Adverse event rates likely underreported due to lack of surveillance
- FDA-approved melanocortin agonists (comparator)
- Weight-based, titrated protocols
- Minimum 24 weeks in Phase III
- Comprehensive AE reporting required
- ECG, BP, HR variability standard
- Mandatory in trials with melanocyte-active agents
- Melanotan-2 bypassed this entire regulatory pathway